Compare ACNT & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNT | RFL |
|---|---|---|
| Founded | 1945 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 133.1M |
| IPO Year | 1995 | 2017 |
| Metric | ACNT | RFL |
|---|---|---|
| Price | $13.59 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.1K | ★ 145.0K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.72 | 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $11.86 | $1.12 |
| 52 Week High | $17.92 | $3.96 |
| Indicator | ACNT | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 36.99 |
| Support Level | $13.53 | $1.22 |
| Resistance Level | $14.50 | $1.58 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 10.58 | 32.63 |
Ascent Industries Co is a specialty chemicals company focused on the development, production, and distribution of tailored, performance-driven chemical solutions. Its customers are spread across energy, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), agriculture, water treatment, pulp and paper, construction, automotive, and other industrial markets. The company's core product portfolio includes surfactants, defoamers, lubricating agents, flame retardants, and specialty intermediates, offered in both petroleum-based and bio-based formulations. Geographically, it generates maximum revenue from the United States, followed by Mexico, Canada, Honduras, Colombia, the Netherlands, Costa Rica, Japan, and other markets.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.